Board approves Q2 and half-year results for September 2026

Results View source PDF Explain this filing

ACUTAAS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+13.3%Reaction day

₹3349.30

prior close

₹3475.30

announcement price

In-mkt

timing

Nifty Smallcap 250market+2.2%+11.1% vs market

Pharmaceuticals peers, median of 173sector+2.0%+11.4% vs sector

On the reaction day the stock moved 11.1 pts more than Nifty Smallcap 250 and 11.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+5.4

15m

+3.1

30m

+7.0

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+13.3+2.2+11.1+2.0+11.4

Next day

+10.2+2.5+7.6+2.6+7.5

+17.6+3.2+14.4+2.6+15.0

+19.7pendingpending+1.9+17.8

—————

15d

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

At its October 27, 2026 meeting, the board approved Acutaas Chemicals' unaudited standalone and consolidated results for the second quarter and half year ended September 30, 2026. It also approved the half-year balance sheet and cash flow statement after Audit Committee review. Statutory auditors Maheshwari and Company issued a limited review report. No financial figures were provided.

Likely market impact

Results are confirmed, but no earnings figures, outlook or dividend details are included, so the effect on shareholder value cannot be judged.